or Try an Advanced Search...

    Technical Analysis for ALGS - Aligos Therapeutics, Inc.

    Grade Last Price % Change Price Change
    B 0.80 6.80% 0.05
    ALGS closed up 6.8 percent on Monday, April 22, 2024, on approximately normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 2
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Flat Down Down
    Historical ALGS trend table...
    Date Alert Name Type % Chg
    Crossed Above 200 DMA Bullish 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    200 DMA Resistance Bearish 6.80%
    Lower Bollinger Band Walk Weakness 6.80%
    Wide Bands Range Expansion 6.80%
    Below Lower BB Weakness 6.80%
    Older End-of-Day Signals for ALGS ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 20 hours ago
    Possible Inside Day about 20 hours ago
    Gap Up Closed about 22 hours ago
    Gap Up Partially Closed about 22 hours ago
    Gapped Up (Partial) about 23 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ALGS Chart by TradingView
    Basic chart:

    Profile

    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Clinical Medicine Alcohol Drug Development Coronavirus Hepatitis B Hepatitis Steatohepatitis Viruses Non Alcoholic Fatty Liver Disease Liver Disease Viral Disease Viral Infections Antiviral Therapies Chronic Hepatitis Viral Infection

    Is ALGS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 9 Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
    Apr 3 Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
    Mar 27 Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?
    Mar 27 Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
    Mar 18 Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
    Mar 14 Aligos Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
    Mar 12 Aligos Therapeutics GAAP EPS of -$0.22 beats by $0.05, revenue of $2.68M beats by $1.08M
    Mar 12 Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
    Mar 5 Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
    Feb 26 Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
    See more ALGS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.38
    52 Week Low 0.54
    Average Volume 448,148
    200-Day Moving Average 0.80
    50-Day Moving Average 0.89
    20-Day Moving Average 0.95
    10-Day Moving Average 0.90
    Average True Range 0.08
    RSI (14) 39.76
    ADX 29.27
    +DI 13.83
    -DI 25.20
    Chandelier Exit (Long, 3 ATRs) 0.85
    Chandelier Exit (Short, 3 ATRs) 0.98
    Upper Bollinger Bands 1.15
    Lower Bollinger Band 0.75
    Percent B (%b) 0.13
    BandWidth 42.05
    MACD Line -0.03
    MACD Signal Line 0.00
    MACD Histogram -0.0339
    Fundamentals Value
    Market Cap 57.68 Million
    Num Shares 72 Million
    EPS -1.89
    Price-to-Earnings (P/E) Ratio -0.42
    Price-to-Sales 3.14
    Price-to-Book 0.93
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.91
    Resistance 3 (R3) 0.90 0.85 0.89
    Resistance 2 (R2) 0.85 0.83 0.86 0.88
    Resistance 1 (R1) 0.83 0.81 0.84 0.84 0.88
    Pivot Point 0.78 0.78 0.79 0.79 0.78
    Support 1 (S1) 0.76 0.76 0.77 0.77 0.73
    Support 2 (S2) 0.71 0.74 0.72 0.72
    Support 3 (S3) 0.69 0.71 0.71
    Support 4 (S4) 0.70